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Open acAbstract Colorectal cancer (CRC) places a considerable burden on individuals and society in
Europe, being the second most common cause of cancer-related death in the region. While ear-
lier diagnosis and advances in treatment have considerably improved survival in recent years,
further progress is needed. One of the greatest challenges associated with the treatment of
CRC is the fact that current therapies for advanced disease are not curative, necessitating
treatment for many years and placing a signiﬁcant healthcare burden on society. To reduce
the burden of CRC, care delivery must be more efﬁcient and cost-effective. In particular,
development of adequate screening programmes is needed, along with chemo-preventative
strategies and newer, more active therapies. Further challenges include the lack of optimal
selection of patients for adjuvant therapy, identiﬁcation of the most appropriate target pop-
ulations for current treatments and the optimum sequence for new molecular targeted agents.
This article outlines current developments and unmet needs in CRC, and provides a detailed
vision for improvements in the management of the disease. Implementation of some of these
strategies will go some way to improving outcomes for patients with CRC.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.26
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Cancer places a considerable burden on society, being
responsible for 29% of male and 23% of female deaths in
Europe in 2008, and 7.6 million deaths globally.1
Against this backdrop, the American Society of Clinical
Oncology (ASCO) has developed a blueprint for action
in an eﬀort to accelerate progress in oncology.2 The
blueprint calls for a new approach to therapeutic devel-
opment, employing molecularly-driven clinical trials
leading to a more cost-eﬀective process. While many
of the proposals outlined in ASCO’s vision are applica-
ble to Europe, the region faces a number of unique chal-
lenges requiring a Europe-focussed approach. This
article, focussing on unmet needs in colorectal cancer
(CRC), forms the ﬁrst in a series of reviews outlining
current requirements in oncology and proposing future
directions in a ‘European call to action’ across the
healthcare community.2. The healthcare burden and the challenges of CRC
CRC has a considerable impact on patients and
healthcare systems in developed countries, and is the
second most common cause of cancer-related death in
Europe.3,4 Around 25% of patients present with meta-
static disease that signiﬁcantly impacts on prognosis.5
For those with localised CRC (Tumour, Nodes, Metas-
tasis [TNM] stages I and II) the 5-year survival rate is as
high as 93%, declining to 60%, 42% and 25% for patients
with TNM stages IIIA, IIIB and IIIC, respectively.
However, most patients with metastatic CRC (mCRC;
stage IV) are not curable, with the 5-year survival rate
falling to less than 10%.6,7
While early diagnosis of CRC in recent years com-
bined with advances in treatment has considerably
improved survival,4 management of the disease remains
challenging and further progress is needed. One problem
associated with treatment is the heterogeneity of the CRC
population.8 In addition, as current therapies for
advanced CRC are not curative, patients require treat-
ment for many years, placing a signiﬁcant healthcare bur-
den on society. For this reason, development of adequate
screening programmes is needed, along with chemo-pre-
ventative strategies and newer, more active therapies.
Additional challenges include the lack of optimal selec-
tion of patients for adjuvant therapy, identiﬁcation of
themost appropriate target populations for current treat-
ments and the optimum sequence for new molecular tar-
geted agents.3. Identifying new pathways in CRC through improved
understanding of pathogenesis
An understanding of the genetics of inherited CRCs
is important in order to identify at-risk individuals andimprove diagnostic and therapeutic approaches. Famil-
ial predisposition is responsible for approximately one-
quarter of CRCs, though hereditary syndromes with a
known genetic defect are responsible for <5% of patients
with CRC (Table 1).8–14
Three key pathways of genetic instability have been
identiﬁed in CRC: chromosomal instability, microsatel-
lite instability and CpG island methylator phenotype
(CIMP), the methylator pathway.14 These pathways are
responsible for both sporadic and inherited cases, the
most prevalent of which is Lynch syndrome, accounting
for 2–4% of CRCs.8 Other common syndromes include
familial adenomatous polyposis (FAP) and serrated pol-
yposis, a recently identiﬁed disease aﬀecting 1 in 3000
individuals undergoing CRC screening.15 While screen-
ing and surveillance strategies are now available for most
inherited CRC syndromes, treatments for primary or sec-
ondary chemoprevention are lacking and new agents are
needed, particularly for early-onset syndromes such as
FAP and Lynch syndrome.
The identiﬁcation of relevant molecular targets for
cancer initiation and/or progression is an important focus
for the development of targeted therapies inCRCand sig-
niﬁcant advances have been made recently as a result of
projects such as the National Cancer Institute’s Cancer
Genome Atlas Network.16 Patients whose tumours
depend on particular targets can then be selected to avoid
or minimise primary resistance to therapy. Mutations in
the adenomatous polyposis coli (APC) and KRAS genes
are thought to be among the earliest events in colorectal
tumorigenesis.17 APC mutation occurs through aberrant
activation of the Wnt/b-catenin signalling pathway, with
mutations within this pathway being responsible for
around 90% of sporadic colon cancers.18 APC is also
the gene responsible for FAP and is a key target for intra-
cellular signalling. A further important molecular target
is epidermal growth factor receptor (EGFR), since
around 10% of CRC tumours and 20–30% of KRAS
wild-type tumours are dependent on the EGFR path-
way.19 EGFR activates multiple signalling pathways,
including RAS/RAF/MEK/ERK and PTEN/PI3K/Akt
(Fig. 1).20,21 RAS/RAF/MEK/ERK is the main pathway
upregulated when EGFR is activated,21 though upregu-
lated genes diﬀer between tumour types, underlining the
need for gene proﬁling for all CRC tumours.
4. Improving survival through advancements in CRC
prevention and diagnosis
Eﬀective screening to detect precursor lesions and
early CRC is critical to reduce the burden of the disease
on the healthcare system. Identiﬁcation of adenomas
before the development of carcinoma not only improves
survival but also reduces cancer incidence. Indeed, the
utility of this strategy has been accepted by the Euro-
pean Commission, which encourages the implementa-
tion of screening programmes throughout Europe.22,23
Table 1
Sporadic and syndromic forms of CRC and associated genetic mutations.8–14
Form of CRC Lifetime CRC risk Pathway Genetic alterations identiﬁed to date
Syndromic
Familial adenomatous polyposis 95% (at 50 years of age) Suppressor APC mutations
Lynch syndrome 50–80% Mutator MMR mutations: hMSH2, hMLH1, hMSH6 and hPMS2
Serrated polyposis 35% Methylator BRAF, KRAS, CIMP-H, MLH1 methylation, MGMT
methylation
Sporadic
Chromosomal instability N/A Suppressor APC mutations/aberrant Wnt/b-catenin signalling
Microsatellite instability N/A Mutator MLH1 gene promoter hypermethylation, BRAF V600E
mutation
CpG island methylator phenotype N/A Methylator CIMP-H
APC, adenomatous polyposis coli; CIMP, CpG island methylator phenotype; CRC, colorectal cancer; MMR, mismatch repair; N/A, not
applicable.
Fig. 1. Epidermal growth factor receptor (EGFR) signalling pathway.
Reproduced from Krasinskas (2011).20 Ligand binding induces
dimerisation and activates the EGFR, and subsequent autophospho-
rylation of tyrosine residues activates downstream signalling. Ras/Raf/
MEK/MAPK is one axis of the EGFR signalling cascade. Activation
of this pathway, via growth factor receptor-bound protein 2 adapter
protein (Grb2) and son of sevenless (SOS), leads to activation of Ras
GTPases and Raf (ARAF, BRAF and CRAF) and MEK (MEK1 and
MEK2) kinases, followed by activation of transcription factors in the
cell nucleus that control cell growth, diﬀerentiation and survival.
PI3K/AKT is the other axis of EGFR signalling that is important in
colorectal carcinogenesis. Activation of this pathway via PI3K results
in conversion of phosphatidylinositol-4,5-bisphosphate (PIP2) to
phosphatidylinositol-3,4,5-trisphosphate (PIP3), which promotes
AKT activation. Activated AKT then activates various targets that
also result in cell growth, diﬀerentiation and survival, paralleling the
Ras/Raf/MEK/MAPK pathway. These two axes are closely related
and some overlap exists. Phosphatase with tensin homology (PTEN) is
a phosphatase that converts PIP3 back to PI2, negatively regulating
the PI3K/AKT pathway.
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familial predisposition) is performed by colonoscopy.While this strategy has been proven to reduce the inci-
dence of new CRCs in countries oﬀering colonoscopy
every 10 years for those >50 years of age (e.g. Ger-
many),24 the technique may not reduce mortality in those
with right-side tumours.25 However, the guaiac-based
faecal occult blood test (gFOBT) or most often the faecal
immunochemical test (FIT) are usually implemented in
organised screening programmes targeting average-risk
populations due to better compliance and higher partici-
pation versus colonoscopy.26 Identiﬁcation of early-stage
disease as a result of large-scale screening has the poten-
tial to increase the population of patients with stage I/II
CRC considerably, underlining further the need for the
development of chemoprevention agents.
Besides adenomatous polyps, it is now clear that pre-
cursor colon epithelial polyps are heterogeneous and
also include serrated polyps, sessile serrated adenomas,
traditional serrated adenomas and mixed polyps.27 The
risk of developing CRC may also diﬀer depending on
polyp type. While the optimum screening method, fre-
quency and follow-up for serrated polyps have not been
determined, the results of recent studies suggest that the
number detected is correlated with the risk of developing
CRC.15 To prevent malignant progression, adequate
detection and endoscopic removal of all polyps seems
advisable, with surgical resection being considered if this
is not feasible.
Daily aspirin is a further potential preventative strat-
egy for patients with Lynch syndrome due to their over-
expression of cyclooxygenase II (COX-2). While pro-
phylactic aspirin has been shown to reduce the incidence
of cancer substantially in Lynch syndrome carriers,28 the
precise dose to be used has yet to be deﬁned. Demon-
stration of the beneﬁt of chemopreventive strategies
and agents is challenging and will require very large
studies.5. Current treatment options and unmet needs in CRC
Treatment for CRC is dependent on a number of fac-
tors, including the disease stage (Table 2),29 tumour
Table 2
American Joint Committee on Cancer (AJCC) staging system for
colorectal cancer.29.
AJCC
stage
TNM stage Deﬁnition
I T1; N0; M0 T1: tumour invades submucosa
I T2; N0; M0 T2: tumour invades muscularis propria
IIa T3; N0; M0 T3: tumour invades through muscularis
propria into subserosa or non-peritonealised
pericolic tissues
IIb T4; N0; M0 T4: tumour directly invades other organs or
structures and/or perforates visceral
peritoneum
IIIa T1 or T2;
N1; M0
T1/2; N1: metastases to 1–3 regional lymph
nodes
IIIb T3 or T4;
N1; M0
T3/4: N1: metastases to 1–3 regional lymph
nodes
IIIc Any T; N2;
M0
N2: metastases to P4 regional lymph nodes
IV Any T; Any
N; M1
M1: distant metastases
T, tumour; N, node; M, metastases.
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availability and cost. For patients with stage I/II
CRC, the primary treatment is surgery, with adjuvant
therapy also used in patients with high-risk stage II dis-
ease. For stage III colon cancer, a chemotherapy dou-
blet including a ﬂuoropyrimidine and oxaliplatin has
clearly improved survival, while neoadjuvant
(chemo)radiotherapy improves the outcome of locally
advanced rectal cancer.30 With the development of a
multimodal strategy along with improved surgical and
pathological care, the local recurrence rate in rectal can-
cer is now <10%. However, many patients still develop
distant metastases, despite an adjuvant treatment,
underlying the need to identify better treatment options
to reduce the occurrence of metastatic disease.
For patients with metastatic disease, <0.5% are cured
by chemotherapy alone; therefore, surgery is the only
curative treatment option. One of the challenges is to
bring more patients with metastatic disease towards
resection with curative intent, though combination che-
motherapy with a doublet of cytotoxic agents plus a bio-
logical targeted agent has the potential to convert
unresectable to resectable metastases.30
While the availability of novel biologicals used in
combination with chemotherapy over the past decade
has had a positive impact on survival in CRC,31 their
optimal integration into the management of mCRC
remains diﬃcult. In particular, identifying the sub-
groups of patients and molecular proﬁles that respond
to diﬀerent targeted agents is challenging. Despite active
research,32 validated predictive biomarkers for angio-
genesis inhibitors are not yet available and, although
interesting data are available for cetuximab and pani-
tumumab,33,34 KRAS mutation status remains the only
validated biomarker used to predict therapeutic eﬃcacyfor anti-EGFR antibodies. Recently, it has been shown
that cancer cells are subject to evolutionary selection
pressure, and patients whose tumours were initially
KRAS wild type can develop diﬀerent KRAS muta-
tions.35–37 This may explain the acquired resistance to
EGFR blockade that occurs in most patients with
KRAS wild-type tumours within months of initiating
therapy. Collection of multiple biopsies will help to
identify novel biomarkers and inform on how tumours
evolve over time and in response to treatment. However,
the development of less invasive methods of monitoring
tumour evolution may be required to improve patient
acceptability. Advances in mutation analysis on liquid
biopsies (plasma or blood samples) may be important
in this regard.38 Every eﬀort must be made to ﬁnd pre-
dictive markers for new biological targeted agents in
development in order to improve aﬀordability for
patients with CRC (and other cancers), since they place
a considerable economic burden on health-care budgets.
Deﬁning the best strategy and sequence of biological
targeted agents is another clinical challenge. However,
there are accumulating data suggesting that the progres-
sion continuation of angiogenesis inhibitors improves
the outcome of patients with mCRC.39 Some patients
may also beneﬁt from early integration of anti-EGFR
antibodies, especially if conversion from unresectable
to resectable disease can be considered.
There is a need for the development of newer, more
active agents in CRC for metastatic disease, adjuvant
treatment and chemoprevention. The unravelling of
the taxonomy of CRC will certainly contribute to the
discovery of new active agents in these diﬀerent situa-
tions. Additionally, the search for molecular markers
in parallel with the development of novel agents and
molecular tests will contribute to the identiﬁcation of
new predictive markers for these agents.
New agents or innovative combinations of new
agents interfering with diﬀerent targets within signal
transduction pathways are also needed (see Table 3).
Intriguingly, the BRAF inhibitor vemurafenib failed to
demonstrate relevant activity in BRAF mutant CRC,40
while this drug has considerable activity in patients with
melanoma harbouring the same mutation.41 Preclinical
studies, however, suggest that dual blockade of BRAF
and EGFR may be required in this population.42 The
clinical activity of novel selective MEK1/2 inhibitors
when used as single agents has also not been robust.43,44
However, these agents may be eﬀective in patients with
KRAS mutations, a population resistant to EGFR inhi-
bition, through inhibition of the key MEK downstream
target kinase, ERK.45 Blockade of the MET pathway
may, therefore, be an important means of delaying or
reverting EGFR resistance.46 Other possible future
areas for drug development include inhibition of the
hepatocyte growth factor pathway, microRNA (miR-
NA) proﬁling and colon cancer stem cells.47
Table 3
New cellular targets in colorectal cancer and novel agents in development.
Molecular target Agents in development Company Development phase
RAF inhibition Vemurafenib (PLX4032) Roche I
Dabrafenib (GSK2118436) GlaxoSmithKline I
LGX818 Novartis I
MEK inhibition Pimasertib (MSC1936369B) Merck I
Selumetinib (AZD6244) AstraZeneca I/II
AS703026 Merck I
GSK1120212 GlaxoSmithKline I/II
ARRY-162 (MEK162) Array Biopharma/Novartis I/II
MET inhibition ARQ197 ArQule/Daiichi Sankyo III
PHA-665752 Pﬁzer Preclinical
Beta-catenin pathway Various inhibitors Avalon/Novartis Preclinical/I
VEGF inhibition Tivozanib Astellas II
VEGF, vascular endothelial growth factor.
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required as the results of trials with agents active in stage
IV CRC have been disappointing in the adjuvant setting
(e.g. irinotecan, bevacizumab and cetuximab).48,49 Addi-
tionally, the role of adjuvant chemotherapy in patients
with stage II disease has been diﬃcult to deﬁne, with
15–20% of individuals relapsing despite such treat-
ment.50 Identifying those who will beneﬁt from adjuvant
treatment in this heterogeneous group of patients is a
major challenge, and selection of the appropriate popu-
lation for clinical development is also diﬃcult.
6. Importance of clinical and molecular biomarkers in
therapeutic development
The use of clinical and molecular biomarkers holds
great potential for individualising treatment for patients
with CRC. Incorporating biomarkers into clinical trials
will allow the selection of smaller, enriched populations,
improving the chance of treatment success. It is becom-
ing clear that CRCs will be divided into 5–6 diﬀerent
subtypes, based on distinct molecular characteristics. It
can be predicted that description of this molecular tax-
onomy of CRC will have profound clinical implications.
Some of these markers are already well established in
clinical practice. In particular, testing for KRAS muta-
tion is now recommended in clinical guidelines to deter-
mine eligibility for EGFR monoclonal antibody
therapy.51,52 Other biomarkers under investigation as
possible positive or negative predictors of EGFR-tar-
geted therapy include BRAF, N-RAS and PIK3CA
(downstream eﬀectors of EGFR signalling). While the
presence of these mutations is associated with a low
response rate to cetuximab, determining their predictive
and prognostic value is challenging as alterations in
these eﬀectors can be inter-related.53
Expression of EGFR ligands such as amphiregulin,
epiregulin, transforming growth factor-a, epidermalgrowth factor, EGFR, PTEN and Fc-receptor polymor-
phisms may also have value in predicting cetuximab
activity. In KRAS wild-type patients there was a signif-
icant association between the expression of both amphi-
regulin and epiregulin, and response to cetuximab, both
alone and in combination with irinotecan.54,55 In addi-
tion, it has been suggested that the combination of
PTEN expression and KRAS mutation status may be
a better predictive marker of response to cetuximab than
KRAS status alone.56 Nevertheless, the use of amphireg-
ulin, epiregulin and PTEN proteins as predictive mark-
ers may be limited by the diﬃculty in establishing cut-oﬀ
and threshold levels for interpretation. Polymorphisms
of Fc receptors (FccRIIa and FccRIIIa) have been asso-
ciated with better outcomes in patients treated with rit-
uximab for follicular lymphoma and trastuzumab for
metastatic breast cancer.57 These ﬁndings may also
translate to CRC, since such alterations were associated
with better rates of progression-free survival (PFS) and
overall survival (OS) in patients with mCRC receiving
second-line cetuximab combination therapy.58 Addi-
tionally, xenograft studies suggest a correlation between
HER2 ampliﬁcation and resistance to cetuximab, with
combined inhibition of HER2 and EGFR inducing
long-lasting tumour regression.59
Despite the plethora of potential markers for
response to EGFR inhibitors there are currently no val-
idated biomarkers for angiogenesis inhibitors. Of the
biomarkers investigated to date (plasma vascular endo-
thelial growth factor [VEGF], single nucleotide poly-
morphisms [SNP], TSP-2, KRAS, BRAF and TP53
mutation status), none have been shown to be predictive
for bevacizumab activity,60–62 although BRAF mutation
status may be prognostic for OS.63
Functional imaging, such as positron emission
tomography and functional magnetic resonance imaging
(MRI), is used increasingly in the assessment of CRC.
Such techniques not only aid diagnosis and tumour
E. Van Cutsem et al. / European Journal of Cancer 49 (2013) 2476–2485 2481characterisation, but can also be used to help establish
patient prognosis and evaluate very early responses to
therapy.64 For example, dynamic contrast-enhanced
MRI can be used to predict the biological response to
angiogenesis inhibitors.65 Nevertheless, the predictive
power of imaging will require comprehensive validation
in clinical trials before incorporation into clinical
practice.
7. Development of new models for clinical trials in CRC
In order to improve eﬃcacy and cost-eﬀectiveness
and reduce toxicity, there is a need to standardise studies
with new agents through smarter, faster clinical trials
involving a niche population and smaller sample sizes
(Table 4). Appropriate patient selection is crucial to
avoid ineﬀective studies, and one aim of new CRC trials
should be to ‘personalise medicine’, selecting speciﬁc
populations and using biomarkers to identify the indi-
viduals most likely to respond, thereby optimising out-
comes. This strategy also spares those unlikely to
beneﬁt from unnecessary toxicity, as well as reducing
cost.66 A multidisciplinary approach is required for this
strategy along with rapid molecular screening. Multiple
tumour biopsies and plasma samples (for circulating free
DNA and miRNA determination) should also be col-
lected from all patients for assessment of known bio-
markers and identiﬁcation of novel biomarkers. One
innovation that will help in this regard is the creation
of platforms such as the European Organisation for
Research and Treatment of Cancer (EORTC) screening
network, which allows patients to be screened for a
number of targets so that the most appropriate trial
and drug can be selected. This database will improveTable 4
Problems associated with the design of clinical trials in CRC and strategie
Issues in clinical trial design Improvement st
Many trials of new treatments for CRC have been
costly and ineﬀective
 Use of niche
 Developmen
 Inclusion of
Selecting populations most likely to respond is
problematic
 Use of rapid
 Collection of
Existing biomarkers must be validated before use
in clinical trials
 Clinical trial
tistical and e
 Prospective R
o Targeted
o Unselecte
o Hybrid d
 Retrospectiv
though use o
Regulatory authorities have not been receptive to
inclusion of biomarkers in clinical trials
 Clinicians m
 Focus shoul
The most appropriate end-points have not been
deﬁned
 Developmen
CRC, colorectal cancer; RCT, randomised controlled trial.trial opportunities for patients with CRC, provide key
information on management in Europe and enable trials
in small populations to be conducted. It will also pre-
pare investigators for breakthroughs in knowledge on
the taxonomy of CRC.
To improve eﬃciency and increase the chance of suc-
cess further, biomarkers should be included early in the
clinical development process (Phase I or II) or co-devel-
oped alongside new agents. While gene signatures may
be used to deﬁne biomarkers, proﬁling is diﬃcult to cor-
relate with clinical practice and prospective validation is
needed. Acceptance of biomarkers by regulatory author-
ities may also be an issue; therefore, clinicians must help
to educate decision-makers about their value, shifting
focus from validation towards identiﬁcation of clinically
relevant end-points. Nevertheless, it is likely that regula-
tory agencies will be more receptive to trials that
robustly select subpopulations of patients who are likely
to gain substantial beneﬁt from a speciﬁc treatment.
One of the challenges facing the development of new
clinical trials in CRC is the need to deﬁne the most
appropriate end-points. Trials have traditionally
employed OS as the primary end-point, though use of
shorter-term end-point(s), if suﬃciently validated, could
signiﬁcantly hasten the translation of advances into clin-
ical practice.67 PFS has been suggested as a surrogate
end-point, though most patients are not treated until
disease progression or unacceptable toxicity occurs
and its use is controversial and unproven.68–70 Possible
alternative end-points under investigation include skin
toxicity and hypertension, which may be future surro-
gate end-points of eﬃcacy for EGFR and angiogenesis
inhibitors, respectively.71 Imaging can also be used to
evaluate early responses to angiogenesis inhibitors ands for improvement.
rategy
populations and smaller sample sizes
t of biomarkers to identify patients likely to respond
biomarkers early in the drug development process
molecular screening
tumour biopsies and plasma samples from all patients
design for biomarker validation is driven by scientiﬁc, clinical, sta-
thical considerations
CTs are the ‘gold standard’ approach and include:
or enrichment designs
d or all-comers designs
esigns
e analysis can be done to speed translation to clinical practice,
f RCTs is essential
ust help to educate regulatory agencies
d be shifted from validation to clinically relevant end-points
t and prospective validation of alternative or surrogate end-points
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prospective validation of alternative end-points is
required before their use in clinical trials.
8. New approaches to the medical management of CRC
Multidisciplinary collaboration will be key to the
future management of CRC, combining surgery,
radiotherapy, radiology, endoscopy, oncology, basic
and translational research and genetics. The harness-
ing of information technology should also be maxi-
mised in order to share and disseminate clinical,
genomic and translational data, and collect details
for as many specimens as possible. While oncology
is already a major focus for most European govern-
ments, future CRC care delivery must become more
eﬃcient and cost-eﬀective. This may require prioritisa-
tion of investment by health authorities into diﬀerent
areas of oncology, such as prevention, screening, early
diagnosis, multidisciplinary treatment, quality of care
and treatments for advanced disease. Nevertheless,
collaboration with industry is likely to be required
for initiatives to be cost-eﬀective.Table 5
Issues in the management of patients with CRC and proposals for address
Management issue
>20% of patients present with metastatic (stage IV) disease at the time of
CRC places a high burden on society
Identifying subpopulations of patients appropriate for targeted therapies i
CRCs are heterogeneous and upregulated genes diﬀer between tumour typ
Most patients develop resistance to EGFR inhibitors after a few months o
Colon cancer precursor polyps are heterogeneous, complicating screening
CRC tumours evolve over time
To reduce the burden of CRC on society, care delivery must be more eﬃc
eﬀective
CRC treatment is not curative and requires long-term treatment
CRC, colorectal cancer; EGFR, epidermal growth factor receptor.Further measures aimed at improving the quality of
care are likely to involve a more patient-focussed
approach to the diagnosis and treatment of CRC, as
well as optimisation of long-term follow-up for cure
patients. Additional areas for improvement include
adherence to local treatment guidelines, coordination
of hospital services and patient access to clinical trials.
One area that has seen an explosion in research in
recent years is gene proﬁling. This technology now
allows the possibility of rapid mass screening for large
numbers of genes at one time. Testing for KRAS muta-
tion status is already commonplace in many European
countries, and the next step is to generate gene signa-
tures in order to identify high-risk subsets of patients.
This is just starting to be used in some regions, though
at present gene signatures have mainly a prognostic
value and still lack a predictive beneﬁt. Reimbursement
remains an issue for gene proﬁling in some countries,
and health authorities may need to be convinced of its
value as its use is not recommended presently in any
guidelines.
A number of innovations for drug delivery and sur-
gery have become available for patients with CRC ining them.
Proposal for addressing
diagnosis  Improvement of screening strategies for earlier
diagnosis
 Rapid access to early diagnosis facilities in
patients with high-risk symptoms
 Development of chemopreventive strategies,
early diagnosis and more active therapies
 Primary prevention (diet and physical exercise)
s problematic  Undertaking gene proﬁling in all patients
es  Undertaking gene proﬁling in all patients
f therapy  Treatment strategies aimed at combined HER2/
EGFR inhibition
 Blockade of the MET pathway
guidance  Detection and removal of all polyps
 Surgical resection if removal is not feasible
 Collection of multiple biopsies from all patients
to monitor tumour evolution over time and in
response to treatment
ient and cost-  Prioritisation of investment by health authori-
ties into diﬀerent areas of oncology
 More eﬃcient patient journey through the levels
of care
 Collaboration with industry to reduce costs
 Patient-focussed approach to diagnosis, treat-
ment and follow-up
 Adherence to guidelines
 Coordination of hospital services, including pal-
liative care
 Improved access to clinical trials
E. Van Cutsem et al. / European Journal of Cancer 49 (2013) 2476–2485 2483recent years. These include hepatic intra-arterial and
intraperitoneal chemotherapy, which allow delivery of
higher-dose concentrations of drugs at the tumour site
while limiting systemic exposure and associated toxic-
ity.73 Additionally, signiﬁcant global investment has
been made in targeted drug delivery using nanotechnol-
ogy, since it has the potential to improve quality of life
and outcomes, and reduce toxicity. The technology is
already being used for early diagnosis and pre-treat-
ment, and to deliver guided chemoprevention and che-
motherapy drugs, controlling the pattern of drug
release and targeting the killing of speciﬁc tumour cells
by local heat ablation activated by ﬂuorescence. Despite
its great potential, however, there may be issues with the
uptake of nanotechnology in some European countries
due to the justiﬁcation of the initial cost and stringent
regulations for radiolabelled treatment (e.g. in France).
9. Summary
This article has identiﬁed a number of key areas con-
cerning the management of patients with CRC that
require a ‘call to action’ in Europe and details a vision
for improvement (Table 5). While a number of improve-
ments have been made in the management of patients
with CRC in recent years, challenges still remain. Incor-
poration of the approaches described here will go some
way to improving the quality of life and survival for
those with this common malignancy.
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